0.395
price up icon17.88%   0.0599
after-market Dopo l'orario di chiusura: .38 -0.015 -3.80%
loading
Precedente Chiudi:
$0.3351
Aprire:
$0.3331
Volume 24 ore:
414.77K
Relative Volume:
2.48
Capitalizzazione di mercato:
$20.01M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.3376
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
+22.67%
1M Prestazione:
+1.02%
6M Prestazione:
-37.24%
1 anno Prestazione:
-70.52%
Intervallo 1D:
Value
$0.3331
$0.422
Intervallo di 1 settimana:
Value
$0.3087
$0.422
Portata 52W:
Value
$0.30
$1.64

Passage Bio Inc Stock (PASG) Company Profile

Name
Nome
Passage Bio Inc
Name
Telefono
(267) 866-0312
Name
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Name
Dipendente
60
Name
Cinguettio
@passage_bio
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
PASG's Discussions on Twitter

Confronta PASG con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PASG
Passage Bio Inc
0.395 20.01M 0 -68.80M -59.06M -1.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-29 Ripresa Wedbush Outperform
2024-09-03 Iniziato Rodman & Renshaw Buy
2022-03-08 Downgrade JP Morgan Overweight → Neutral
2022-01-19 Downgrade Goldman Buy → Neutral
2021-07-01 Iniziato Raymond James Outperform
2021-06-15 Iniziato BTIG Research Buy
2021-03-04 Aggiornamento Goldman Neutral → Buy
2021-02-04 Iniziato Guggenheim Buy
2021-01-25 Iniziato Wedbush Outperform
2021-01-04 Aggiornamento JP Morgan Neutral → Overweight
2020-12-11 Iniziato Citigroup Neutral
2020-08-14 Downgrade JP Morgan Overweight → Neutral
2020-06-25 Downgrade Goldman Buy → Neutral
2020-03-25 Iniziato Chardan Capital Markets Buy
2020-03-24 Iniziato Cowen Outperform
2020-03-24 Iniziato Goldman Buy
2020-03-24 Iniziato JP Morgan Overweight
Mostra tutto

Passage Bio Inc Borsa (PASG) Ultime notizie

pulisher
Apr 30, 2025

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus

Apr 30, 2025
pulisher
Apr 29, 2025

Fierce Biotech Layoff Tracker 2025: Entrada cuts 20% of workforce; Ono lays off 83 staffers - Fierce Biotech

Apr 29, 2025
pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 09, 2025

Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025
pulisher
Apr 03, 2025

GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com

Apr 03, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 - Investing.com

Mar 31, 2025
pulisher
Mar 28, 2025

Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com

Mar 27, 2025
pulisher
Mar 25, 2025

Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech

Mar 25, 2025
pulisher
Mar 23, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo

Mar 23, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 16, 2025

Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo

Mar 16, 2025
pulisher
Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo

Mar 13, 2025
pulisher
Mar 09, 2025

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN

Mar 09, 2025
pulisher
Mar 08, 2025

Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq

Mar 07, 2025
pulisher
Mar 07, 2025

FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa

Mar 04, 2025

Passage Bio Inc Azioni (PASG) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Capitalizzazione:     |  Volume (24 ore):